KR102393711B1 - 자가면역 질환의 치료에 반응하는 대상체의 식별 방법 및 그의 치료를 위한 조성물 - Google Patents

자가면역 질환의 치료에 반응하는 대상체의 식별 방법 및 그의 치료를 위한 조성물 Download PDF

Info

Publication number
KR102393711B1
KR102393711B1 KR1020167011472A KR20167011472A KR102393711B1 KR 102393711 B1 KR102393711 B1 KR 102393711B1 KR 1020167011472 A KR1020167011472 A KR 1020167011472A KR 20167011472 A KR20167011472 A KR 20167011472A KR 102393711 B1 KR102393711 B1 KR 102393711B1
Authority
KR
South Korea
Prior art keywords
delete delete
subject
pharmaceutical composition
cells
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167011472A
Other languages
English (en)
Korean (ko)
Other versions
KR20160065934A (ko
Inventor
데니스 엘. 파우스트만
Original Assignee
더 제너럴 하스피탈 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 제너럴 하스피탈 코포레이션 filed Critical 더 제너럴 하스피탈 코포레이션
Publication of KR20160065934A publication Critical patent/KR20160065934A/ko
Application granted granted Critical
Publication of KR102393711B1 publication Critical patent/KR102393711B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
KR1020167011472A 2013-10-17 2014-10-16 자가면역 질환의 치료에 반응하는 대상체의 식별 방법 및 그의 치료를 위한 조성물 Active KR102393711B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892140P 2013-10-17 2013-10-17
US61/892,140 2013-10-17
PCT/US2014/060908 WO2015057968A2 (en) 2013-10-17 2014-10-16 Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same

Publications (2)

Publication Number Publication Date
KR20160065934A KR20160065934A (ko) 2016-06-09
KR102393711B1 true KR102393711B1 (ko) 2022-05-04

Family

ID=52828855

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167011472A Active KR102393711B1 (ko) 2013-10-17 2014-10-16 자가면역 질환의 치료에 반응하는 대상체의 식별 방법 및 그의 치료를 위한 조성물

Country Status (5)

Country Link
US (2) US12174188B2 (https=)
JP (4) JP6560200B2 (https=)
KR (1) KR102393711B1 (https=)
CN (3) CN111879948A (https=)
WO (1) WO2015057968A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9744210B2 (en) 2012-12-27 2017-08-29 Massachusetts Eye & Ear Infirmary Treatment of rhinosinusitis with P-glycoprotein inhibitors
CN111879948A (zh) * 2013-10-17 2020-11-03 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
EP3355914B1 (en) * 2015-09-29 2024-03-06 The General Hospital Corporation A composition comprising bcg for reducing cholesterol.
WO2017123933A1 (en) * 2016-01-15 2017-07-20 Massachusetts Eye And Ear Infirmary Secreted p-glycoprotein is a non-invasive biomarker of chronic rhinosinusitis
CN110198732A (zh) * 2016-12-15 2019-09-03 泰伦基国际有限公司 一种促进胰岛素受体底物-2表达的方法
US11077179B2 (en) * 2017-08-10 2021-08-03 Epicgenetics, Inc. Method for treating fibromyalgia and chronic fatigue syndrome
CN109055523A (zh) * 2018-07-16 2018-12-21 中山大学附属第三医院（中山大学肝脏病医院） Tnfr2基因及其编码蛋白的应用
KR102282342B1 (ko) * 2018-11-20 2021-07-27 아주대학교산학협력단 베체트병 진단 또는 예후 예측용 바이오마커 조성물
WO2020198232A1 (en) 2019-03-25 2020-10-01 Massachusetts Eye And Ear Infirmary Methods and compositions to treat and diagnose diseases or pathologies associated with inflammation of the sinuses and nasal cavity
CN110804643B (zh) * 2019-10-29 2022-06-21 同济大学 一种体外评价卡介苗对中性粒细胞活性影响的方法
CN112806322B (zh) * 2021-03-22 2022-08-16 石河子大学 一种构建色素脱失模型的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229785A1 (en) 2002-11-15 2004-11-18 Denise Faustman Screening methods to identify treatments for autoimmune disease

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309418A (en) 1980-03-25 1982-01-05 Sloan-Kettering Research Institute For Cancer Anti-tumor agent from human serum and process
FR2513124B1 (fr) 1981-07-21 1989-11-17 Hayashibara Biochem Lab Production et applications du facteur de lyse des cellules-cibles
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5288852A (en) 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US4879226A (en) 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
DE3423234A1 (de) 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677064A (en) 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
EP0368367A1 (en) 1984-12-21 1990-05-16 Biogen, Inc. Purification, production and use of tumor necrosis factors
US4681760A (en) 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
US5059530A (en) 1985-09-30 1991-10-22 Suntory Ltd. Expression vector for human TNF
US5002876A (en) 1986-09-22 1991-03-26 Phillips Petroleum Company Yeast production of human tumor necrosis factor
US4985241A (en) 1986-11-21 1991-01-15 Cetus Corporation Therapeutic combination of free-radical scavenger and tumor necrosis factor
US4963354A (en) 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US5215743A (en) 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5370870A (en) 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
US5283058A (en) 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5166142A (en) 1991-06-10 1992-11-24 University Of Rochester Use of type ia antiarrhythmic agents to lower blood lipids
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6984380B1 (en) 1991-08-02 2006-01-10 Denise L. Faustman Treatment of diseases involving faulty MHC class I antigen complex presentation
DE69232798T2 (de) 1991-08-02 2003-07-24 Denise L Faustman Diagnose und behandlung von autoimmunkrankheiten
US5139481A (en) 1991-08-07 1992-08-18 The General Hospital Corporation Treatment for type II diabetes
US5843425A (en) 1992-02-19 1998-12-01 The General Hospital Corporation Transplantation and graft-versus-host-disease
DK0639979T3 (da) 1992-04-23 2002-12-02 Sloan Kettering Inst Cancer Ligand for c-kit-receptoren og fremgangsmåde til anvendelse heraf
WO1994009137A1 (en) 1992-10-15 1994-04-28 Genentech, Inc. Antibodies against type 2 tumor necrosis factor receptor
US5843452A (en) 1992-11-09 1998-12-01 Pharmagenesis, Inc. Immunotherapy composition and method
EP0612529B1 (en) 1993-01-22 2000-04-05 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Therapeutic agent for NIDDM
US5728385A (en) 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
MX9700198A (es) * 1994-07-08 1997-04-30 Dartmouth College Compuestos peptidos de proinsulina para detectar y tratar diabetes tipo 1.
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US6056952A (en) 1995-08-30 2000-05-02 The United States Of America As Represented By The Department Of Health And Human Services Selective elimination of T cells that recognize specific preselected targets
US6110206A (en) 1995-09-15 2000-08-29 Crosscart, Inc. Anterior cruciate ligament xenografts
US5874306A (en) 1996-12-12 1999-02-23 The Regents Of The University Of California Culturing human pancreatic endocrine cells in medium containing extracellular matrix from human bladder carcinoma cells
US5837467A (en) * 1997-01-21 1998-11-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for predicting the response to treatment with BCG of superficial bladder carcinoma
US6046031A (en) 1997-01-21 2000-04-04 Human Genome Sciences, Inc. Metalloproteinases
US6177076B1 (en) 1997-12-09 2001-01-23 Thomas Jefferson University Method of treating bladder cancer with wild type vaccinia virus
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6284879B1 (en) 1998-04-16 2001-09-04 The General Hospital Corporation Transport associated protein splice variants
US6165737A (en) 1998-04-16 2000-12-26 The University Of Texas System Board Of Regents DNA fragmentation factor involved in apoptosis
EP1077724A2 (en) 1998-04-17 2001-02-28 The University Of Vermont Methods and products related to metabolic interactions in disease
JP2002515459A (ja) 1998-05-18 2002-05-28 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ 喘息および他のアレルギー性症状を治療するための方法およびｔｎｆ−ｒｉｉ（ｐ７５）アゴニストを含む組成物の使用
US7485293B1 (en) 1999-02-18 2009-02-03 Faustman Denise L Method for inhibiting transplant rejection
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
CA2392615A1 (en) 1999-12-06 2001-06-07 The General Hospital Corporation Pancreatic stem cells and their use in transplantation
US6414218B1 (en) 2000-01-18 2002-07-02 The General Hospital Corporation Mouse model for rheumatoid arthritis
AU2001294834A1 (en) 2000-09-26 2002-04-08 Beth Israel Deaconess Medical Center Recombinant bcg vaccines for the prevention and treatment of cancer
US20040031066A9 (en) 2001-01-18 2004-02-12 Faustman Denise L. Mouse model for rheumatoid arthritis
US20020146753A1 (en) 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
US20040235160A1 (en) 2001-08-07 2004-11-25 Mitsuo Nishikawa Process for preparing hematopoietic stem cells
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
AU2002952834A0 (en) * 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
CN1448724A (zh) * 2003-05-13 2003-10-15 上海晶泰生物技术有限公司 1型糖尿病相关抗原抗体同时检测蛋白芯片
EP1687411B1 (en) 2003-09-26 2015-05-06 The Regents Of The University Of Michigan Hematopoietic stem cell identification and isolation
EP1678317A2 (en) 2003-10-17 2006-07-12 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with mosaic serine protease (msp)
JPWO2005084697A1 (ja) 2004-03-04 2007-11-29 門脇　孝 アディポネクチン受容体発現制御剤
US8563308B2 (en) 2004-03-10 2013-10-22 The Rockefeller University Culture-expanded T suppressor cells and methods of use thereof
US20070135338A1 (en) 2004-03-31 2007-06-14 Karyn O'neil Human GLP-1 mimetibodies, compositions, methods and uses
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
JP2008505176A (ja) 2004-06-30 2008-02-21 コンビナトアールエックス インコーポレーティッド 代謝障害を治療するための方法および試薬
WO2006006165A2 (en) 2004-07-12 2006-01-19 Yeda Research And Development Co. Ltd. Use of erythropoietin for enhancing immune responses and for treatment of lymphoproliferative disorders
CN103251953A (zh) 2004-07-19 2013-08-21 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
US20080102054A1 (en) 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
US9081017B2 (en) 2005-04-11 2015-07-14 Cambridge Enterprise Limited Methods for identifying modulators of tumor necrosis factor receptors
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US7867765B2 (en) 2005-12-28 2011-01-11 The General Hospital Corporation Blood cell sorting methods and systems
CN101687019A (zh) * 2007-04-24 2010-03-31 迪亚米德治疗股份公司 用于治疗自身免疫性疾病和癌症的药物和方法
JP2009014626A (ja) * 2007-07-06 2009-01-22 Medibic:Kk Ｂｃｇによる治療効果の予測方法
ES2560097T3 (es) 2008-02-04 2016-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Procedimientos y composiciones de tratamiento de trastornos mitocondriales
US20090257982A1 (en) 2008-04-11 2009-10-15 Scheiber Lane Bernard medical device for treating diabetes mellitus, obesity, chronic fatigue, aging, and other medical conditions by utilizing modified virus virions to insert messenger ribonucleic acid molecules into cells
US20110177592A1 (en) 2008-07-11 2011-07-21 Faustman Denise L Magnetic apparatus for blood separation
NZ592111A (en) * 2008-09-30 2012-03-30 Baylor Res Inst Methods to reduce b-helper t cells to treat autoimmune diseases using il-12 antibodies
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
EP2192197A1 (en) * 2008-11-27 2010-06-02 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Predicting clinical response to treatment with a soluble tnf-antagonist or tnf, or a tnf receptor agonist
US20100151062A1 (en) 2008-12-16 2010-06-17 Bruno Stefanon Determining nutrients for animals through gene expression
US8362218B2 (en) 2009-04-17 2013-01-29 New York University School Of Medicine Peptides targeting TNF family receptors and antagonizing TNF action, compositions, methods and uses thereof
CN102421435A (zh) 2009-04-28 2012-04-18 贝林格尔.英格海姆国际有限公司 使用PKC-θ抑制剂的免疫性疾病的离体治疗
WO2011005779A2 (en) * 2009-07-07 2011-01-13 University Of Southern California Biomarkers for the early detection of autoimmune diseases
EP2292260A1 (en) 2009-08-13 2011-03-09 Institut Pasteur Use of mycobacterium bovis BCG killed by extended freeze drying (EFD) for preventing or treating atherosclerosis
CN102725634B (zh) * 2009-08-24 2016-01-20 纽约哥伦比亚大学理事会 用于测定cd8+t细胞的健康的测试法
JO3183B1 (ar) * 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
MX374075B (es) * 2010-03-26 2025-03-05 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
EP2556161A4 (en) 2010-04-09 2013-11-06 Gen Hospital Corp METHOD FOR TREATING AUTOIMMUNE DISEASES
EP2585828A4 (en) * 2010-06-25 2014-03-12 Glaxo Group Ltd METHOD FOR THE TREATMENT OF PATIENTS WITH IMMUNE SYSTEM DISEASES
US20120045435A1 (en) 2010-08-18 2012-02-23 Theresa Deisher Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
JP2012108112A (ja) * 2010-10-27 2012-06-07 Arkray Inc ＨｂＡ１ｃ測定結果の表示方法、表示装置、及び表示プログラム
WO2012122464A1 (en) 2011-03-10 2012-09-13 New York University Methods and compositions for modulating tnf/tnfr signaling
EP2720690A4 (en) 2011-06-16 2014-12-31 Childrens Medical Center COMBINED CHEMICAL MODIFICATION OF SPHINGOSIN-1-PHOSPHATE (S1P) AND CXCR4 SIGNALING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND TRANSPLANT
EP2788476B1 (en) 2011-12-08 2019-05-22 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2013131083A1 (en) 2012-03-02 2013-09-06 Winthrop-University Hospital METHOD FOR USING PROBE BASED PCR DETECTION TO MEASURE THE LEVELS OF CIRCULATING DEMETHYLATED β CELL DERIVED DNA AS A MEASURE OF β CELL LOSS IN DIABETES
JP5900044B2 (ja) 2012-03-12 2016-04-06 オムロンヘルスケア株式会社 糖尿病治療支援装置、糖尿病治療支援方法、糖尿病治療支援プログラム
WO2014075098A1 (en) 2012-11-09 2014-05-15 The General Hospital Corporation Methods and kits for diagnosing sjögren's syndrome
EP3936137A1 (en) 2013-02-07 2022-01-12 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
JP6595984B2 (ja) 2013-05-14 2019-10-23 メタボロン，インコーポレイテッド 腎機能に関連付けられるバイオマーカーおよびそれを使用する方法
CN111879948A (zh) 2013-10-17 2020-11-03 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
EP3355914B1 (en) 2015-09-29 2024-03-06 The General Hospital Corporation A composition comprising bcg for reducing cholesterol.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229785A1 (en) 2002-11-15 2004-11-18 Denise Faustman Screening methods to identify treatments for autoimmune disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ban et al., PNAS, Vol. 105, No. 36, 2008, pp. 13644-13649.
L. Faustman et al., PLOS ONE, Vol. 7, No. 8, 2012, pp. 1-16.*
N.Munshi et al., The American Journal of Medicine, Vol. 122, No. 4, 2009, pp. 395-397.

Also Published As

Publication number Publication date
JP2016540195A (ja) 2016-12-22
CN111879948A (zh) 2020-11-03
CN111239415B (zh) 2024-03-26
US20160245808A1 (en) 2016-08-25
US12174188B2 (en) 2024-12-24
JP2022023882A (ja) 2022-02-08
JP6964632B2 (ja) 2021-11-10
JP2024001123A (ja) 2024-01-09
CN111239415A (zh) 2020-06-05
JP6560200B2 (ja) 2019-08-14
JP2019215354A (ja) 2019-12-19
US20250110122A1 (en) 2025-04-03
WO2015057968A3 (en) 2015-06-11
CN105829885B (zh) 2020-08-18
WO2015057968A2 (en) 2015-04-23
KR20160065934A (ko) 2016-06-09
CN105829885A (zh) 2016-08-03

Similar Documents

Publication Publication Date Title
US20250110122A1 (en) Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
Van Schouwenburg et al. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients
KR102895422B1 (ko) 세포성 및 체액성 면역을 도출하기 위한 인간 중간엽 줄기 세포의 사용 방법
US12006366B2 (en) Methods and compositions for preventing type 1 diabetes
Mallone et al. Biomarkers for immune intervention trials in type 1 diabetes
KR20150022878A (ko) 당뇨병 바이오마커
KR20240144440A (ko) 인간에게 투여하기 위해 제제화된 항-cd28 인간화 항체
Saini et al. Activated effector and memory T cells contribute to circulating sCD30: potential marker for islet allograft rejection
Baggio et al. Sex-dependent PD-L1/sPD-L1 trafficking in human endothelial cells in response to inflammatory cytokines and VEGF
Cantley et al. Islet cells in human type 1 diabetes: from recent advances to novel therapies–a symposium-based roadmap for future research
Srivastava et al. A microenvironment-driven HLA-II-associated insulin neoantigen elicits persistent memory T cell activation in diabetes
Sharwood et al. Therapeutic plasma exchange normalizes insulin‐mediated response in a child with type 1 diabetes and insulin autoimmune syndrome
HK40036872A (en) Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
Bleesing et al. Human T cell activation induces the expression of a novel CD45 isoform that is analogous to murine B220 and is associated with altered O-glycan synthesis and onset of apoptosis
HK40028012A (en) Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
HK40028012B (zh) 鉴定响应於用於自身免疫性疾病的治疗的受试者的方法以及用於治疗该疾病的组合物
HK1227487A1 (en) Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
HK1227487B (zh) 鉴定响应於用於自身免疫性疾病的治疗的受试者的方法以及用於治疗该疾病的组合物
JPWO2009020142A1 (ja) リガンド−レセプター結合阻害活性の測定方法
ITRM20110248A1 (it) Method to prognose viral infection by measuring t cell response or auto-antibodies to apoptotic epitopes
WO2014018931A1 (en) Methods and compositions for treating autoimmune disease
Krug et al. Induction of insulin antibodies and insulin allergy under alpha-interferon treatment of renal cell carcinoma in a patient with insulin-treated diabetes mellitus–a case report
TWI889747B (zh) 用於預防第1型糖尿病的方法及組成物
NZ794292A (en) Methods of using human mesenchymal stem cells to effect cellular and humoral immunity
Lubetzki‐Korn et al. Human alpha‐fetoprotein–rich fraction inhibits galactocerebroside antibody–mediated lysis of oligodendrocyte in vitro

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4